Literature DB >> 23186809

Chimeric natriuretic peptide ACNP stimulates both natriuretic peptide receptors, the NPRA and NPRB.

Xudong Zhu1, Yong Wang, Anja Schwiebs, Thomas Walther.   

Abstract

Here, we investigated the receptor profile of the newly designed natriuretic peptide (NP) ACNP consisting of the N- and C-terminus of human ANP and the ring structure of CNP, its potency/efficacy in stimulating cGMP generation in primary cells, and its stability towards peptidase activity. ACNP stimulated both human natriuretic peptide receptors (NPRs), NPRA and NPRB, as potent as their native ligands in receptor transfected cells. Consequently, ACNP was more efficient in generating cGMP compared to ANP, BNP, and CNP, in primary cells expressing both NPRs. All NPs have been similarly degraded by neprilysin, except the neprilysin-resistant BNP. However, ACNP was fastest degraded in serum, while CNP was most stable. Congruently, CNP but not ACNP reduced blood pressure most significantly after acute peptide infusion in normotensive mice. Our data identify ACNP as the first compound being able to stimulate both natriuretic receptors with similar potency and efficacy as their respective ligands.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186809     DOI: 10.1016/j.mce.2012.11.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  2 in total

1.  The virtually mature B-type natriuretic peptide (BNP1-32) is a precursor for the more effective BNP1-30.

Authors:  Anja Schwiebs; Yong Wang; Andrew M Moore; Xudong Zhu; Kristin Pankow; Wolf-Eberhard Siems; Thomas Walther
Journal:  Br J Pharmacol       Date:  2020-02-19       Impact factor: 8.739

2.  A New Chimeric Natriuretic Peptide, CNAAC, for the Treatment of Left Ventricular Dysfunction after Myocardial Infarction.

Authors:  Shu-Miao Zhang; Hong-Lin Zhao; Xiao-Ming Gu; Juan Li; Na Feng; Yue-Min Wang; Rong Fan; Wen-Sheng Chen; Jian-Ming Pei
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.